Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.
Iris E BeldhuisJ M Ter MaatenS M FigarskaK DammanP S PangB GreenbergB A DavisonG CotterT SeverinC GimpelewiczG M FelkerG FilippatosJ R TeerlinkM MetraA A VoorsPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2023)
Despite the significant improvement in renal function by serelaxin in patients with acute HF, the potential beneficial treatment effect was not mediated by improvement in renal function. These data suggest that improvement in renal function might not be a suitable surrogate marker for potential treatment efficacy in future studies with novel relaxin agents in acute HF. Central illustration. Conceptual model explaining mediation analysis; treatment efficacy of heart failure therapies mediated by renal function.